Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOD1 | Q9Y239 | 7/20 | 0.44 |
| ▸ | ALB | P02768 | 1/20 | 0.41 |
| ▸ | TLR2 | O60603 | 1/20 | 0.41 |
| ▸ | SIRT5 | Q9NXA8 | 3/20 | 0.40 |
| ▸ | GNPAT | O15228 | 1/20 | 0.37 |
| ▸ | NMT2 | O60551 | 1/20 | 0.36 |
| ▸ | NMT1 | P30419 | 1/20 | 0.36 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.35 |
| ▸ | PRKACA | P17612 | 1/20 | 0.35 |
| ▸ | AKT3 | Q9Y243 | 1/20 | 0.35 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18174546 | 0.91 | ALB (0.49) | NOD1ALBTLR2SIRT5ROCK2 | |
| SCHEMBL24461841 | 0.91 | ALB (0.49) | NOD1ALBTLR2SIRT5ROCK2 | |
| SCHEMBL24239462 | 0.87 | ALB (0.44) | NOD1ALBTLR2SIRT5NMT2 | |
| SCHEMBL24592963 | 0.86 | SIRT5 (0.47) | NOD1TLR2SIRT5GNPATNMT2 | |
| SCHEMBL25454947 | 0.84 | TLR2 (0.39) | NOD1ALBTLR2SIRT5 | |
| SCHEMBL21305215 | 0.84 | ALB (0.44) | NOD1ALBTLR2SIRT5ROCK2 | |
| SCHEMBL14586429 | 0.83 | TLR2 (0.54) | NOD1TLR2SIRT5 | |
| SCHEMBL24817235 | 0.83 | TLR2 (0.52) | TLR2SIRT5NMT2NMT1ROCK2 | |
| SCHEMBL22473591 | 0.81 | TLR2 (0.39) | NOD1ALBTLR2SIRT5NMT2 | |
| SCHEMBL23382257 | 0.81 | NOD1 (0.36) | NOD1ALBTLR2SIRT5ROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8044174-B2 | Peptides and polypeptides which may be used to increase platelets or platelet precursors (e.g., megakaryocytes) in a mammal | AMGEN INC. (US) | 2011-10-25 | — | — | US | disclosed |
| US-20110071077-A1 | Thrombopoietic Compounds | AMGEN INC. (US) | 2011-03-24 | — | — | US | disclosed |
| US-20090053242-A1 | Thrombopoietic compounds | AMGEN INC. (US) | 2009-02-26 | — | — | US | disclosed |
| US-20070142295-A1 | Thrombopoietic compounds | AMGEN INC. (US) | 2007-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090053242-A1 | Thrombopoietic compounds | MPL, THPO, PDGFA | NOD1 4743/4885ALB 1932/4885TLR2 2052/4885 |
| US-20070142295-A1 | Thrombopoietic compounds | MPL, THPO, PDGFA | NOD1 4795/4885ALB 2993/4885TLR2 3064/4885 |
| US-20110071077-A1 | Thrombopoietic Compounds | MPL, THPO, PDGFA | NOD1 4743/4885ALB 1932/4885TLR2 2052/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.